Modification of Apremilast from Pills to Aerosol a Future Concept
Background: Inhaled drugs have been available in the market for several years and for several diseases. Drugs for chronic obstructive pulmonary disease, cystic fibrosis, and diabetes have been used for several years. In the field of drug modification, these drugs range from tablets to aerosol. Metho...
Guardado en:
Autores principales: | Paul Zarogoulidis, Christoforos Kosmidis, Nikolaos Kougkas, Aimilios Lallas, Dimitris Petridis, Wolfgang Hohenforst-Schmidt, Haidong Huang, Lutz Freitag, Chrisanthi Sardeli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2f545a093e504e6bba8c1b6b243e6a2d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?
por: Zoe Apalla, et al.
Publicado: (2019) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan M, et al.
Publicado: (2021) -
Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats
por: Anwer MK, et al.
Publicado: (2019) -
Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
por: Lanna C, et al.
Publicado: (2019) -
Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
por: Smirnova LM, et al.
Publicado: (2019)